PURPOSE: Previous literature suggests that parents often wish to continue cancer-directed therapy for their children with incurable cancer. We assessed parents' experiences with treatment for their children with cancer and no realistic chance of cure. PATIENTS AND METHODS: We administered questionnaires to 141 parents of children with cancer who died after receiving care at one of two cancer centers. Parents were asked whether the child benefited and suffered from treatment administered after the parent recognized that cure was not a realistic expectation, and whether they would recommend cancer-directed therapy to other families of children with advanced cancer. RESULTS: Fifty-three (38%) of 141 children received cancer-directed therapy after the parent recognized that the child had no realistic chance for cure. Most of these parents felt that their child had experienced at least some suffering resulting from the therapy (61%, 31 of 51) and little to no benefit (57%, 29 of 51). Fifty-one (38%) of 135 parents overall would recommend standard chemotherapy and 46 (33%) of 140 would recommend experimental chemotherapy to families of children with advanced cancer. Even parents who would not recommend standard chemotherapy generally felt the physician should offer it (91%, 88 of 97). Parents who reported that their children experienced suffering resulting from cancer-directed therapy (odds ratio = 0.46; P = .02) were less likely to recommend standard chemotherapy to other families. CONCLUSION: Although many parents choose treatment for their children with incurable cancer, bereaved parents often would not recommend such therapy. Parents who felt their children suffered as a result of cancer treatment were particularly unlikely to recommend it.
PURPOSE: Previous literature suggests that parents often wish to continue cancer-directed therapy for their children with incurable cancer. We assessed parents' experiences with treatment for their children with cancer and no realistic chance of cure. PATIENTS AND METHODS: We administered questionnaires to 141 parents of children with cancer who died after receiving care at one of two cancer centers. Parents were asked whether the child benefited and suffered from treatment administered after the parent recognized that cure was not a realistic expectation, and whether they would recommend cancer-directed therapy to other families of children with advanced cancer. RESULTS: Fifty-three (38%) of 141 children received cancer-directed therapy after the parent recognized that the child had no realistic chance for cure. Most of these parents felt that their child had experienced at least some suffering resulting from the therapy (61%, 31 of 51) and little to no benefit (57%, 29 of 51). Fifty-one (38%) of 135 parents overall would recommend standard chemotherapy and 46 (33%) of 140 would recommend experimental chemotherapy to families of children with advanced cancer. Even parents who would not recommend standard chemotherapy generally felt the physician should offer it (91%, 88 of 97). Parents who reported that their children experienced suffering resulting from cancer-directed therapy (odds ratio = 0.46; P = .02) were less likely to recommend standard chemotherapy to other families. CONCLUSION: Although many parents choose treatment for their children with incurable cancer, bereaved parents often would not recommend such therapy. Parents who felt their children suffered as a result of cancer treatment were particularly unlikely to recommend it.
Authors: P S Hinds; L Oakes; W Furman; P Foppiano; M S Olson; A Quargnenti; J Gattuso; B Powell; D K Srivastava; D Jayawardene; J T Sandlund; C Strong Journal: Oncol Nurs Forum Date: 1997-10 Impact factor: 2.172
Authors: D M Ashley; L Meier; T Kerby; F M Zalduondo; H S Friedman; A Gajjar; L Kun; P K Duffner; S Smith; D Longee Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: Sharyn N Lewin; Barbara M Buttin; Matthew A Powell; Randall K Gibb; Janet S Rader; David G Mutch; Thomas J Herzog Journal: Gynecol Oncol Date: 2005-09-02 Impact factor: 5.482
Authors: Jennifer W Mack; Joanne M Hilden; Jan Watterson; Caron Moore; Brian Turner; Holcombe E Grier; Jane C Weeks; Joanne Wolfe Journal: J Clin Oncol Date: 2005-09-19 Impact factor: 44.544
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Veronica Dussel; Kira Bona; John A Heath; Joanne M Hilden; Jane C Weeks; Joanne Wolfe Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: Wendy G Lichtenthal; Kailey E Roberts; Corinne Catarozoli; Elizabeth Schofield; Jason M Holland; Justin J Fogarty; Taylor C Coats; Lamia P Barakat; Justin N Baker; Tara M Brinkman; Robert A Neimeyer; Holly G Prigerson; Talia Zaider; William Breitbart; Lori Wiener Journal: Palliat Med Date: 2020-02-05 Impact factor: 4.762
Authors: Erica C Kaye; Courtney A Gushue; Samantha DeMarsh; Jonathan Jerkins; April Sykes; Zhaohua Lu; Jennifer M Snaman; Lindsay Blazin; Liza-Marie Johnson; Deena R Levine; R Ray Morrison; Justin N Baker Journal: Pediatr Blood Cancer Date: 2017-12-08 Impact factor: 3.167